Stay updated on Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:25:22.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a Phase 1/2 clinical trial evaluating the safety and preliminary activity of Nivolumab in combination with Vorolanib in patients with refractory thoracic tumors, including Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, and Thymic Carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:11.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    58%
    Check dated 2024-05-22T21:03:46.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:36:51.000Z thumbnail image

Stay in the know with updates to Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial page.